BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Sun L, Li PB, Yao YF, Xiu AY, Peng Z, Bai YH, Gao YJ. Proteinase-activated receptor 2 promotes tumor cell proliferation and metastasis by inducing epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma. World J Gastroenterol 2018; 24(10): 1120-1133 [PMID: 29563756 DOI: 10.3748/wjg.v24.i10.1120]
URL: https://www.wjgnet.com/1007-9327/full/v24/i10/1120.htm
Number Citing Articles
1
Yuhong Jiang, Xin Zhuo, Yue Wu, Xiujuan Fu, Canquan Mao. PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expressionBiochimica et Biophysica Acta (BBA) - Molecular Cell Research 2022; 1869(1): 119144 doi: 10.1016/j.bbamcr.2021.119144
2
Kiman Kim, Jinyong Lee, Sungho Ghil. The regulators of G protein signaling RGS 16 and RGS 18 inhibit protease‐activated receptor 2/Gi/o signaling through distinct interactions with Gα in live cells FEBS Letters 2018; 592(18): 3126 doi: 10.1002/1873-3468.13220
3
Kaushik Das, Subhojit Paul, Arpana Singh, Arnab Ghosh, Abhishek Roy, Shabbir Ahmed Ansari, Ramesh Prasad, Ashis Mukherjee, Prosenjit Sen. Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transitionJournal of Biological Chemistry 2019; 294(37): 13681 doi: 10.1074/jbc.RA119.008619
4
Kenjiro Kaji, Noriyuki Kaji, Masatoshi Hori, Kosei Sakai, Tomohiro Yonezawa, Shingo Maeda. Protease-Activated Receptor-2 Is Associated With Adverse Outcomes in Canine Mammary CarcinomaVeterinary Pathology 2021; 58(1): 53 doi: 10.1177/0300985820963087
5
Nisha R. Pawar, Marguerite S. Buzza, Toni M. Antalis. Membrane-Anchored Serine Proteases and Protease-Activated Receptor-2–Mediated Signaling: Co-Conspirators in Cancer ProgressionCancer Research 2019; 79(2): 301 doi: 10.1158/0008-5472.CAN-18-1745
6
Juncheng Guo, Min Guo, Jinfang Zheng. Inhibition of Bone Morphogenetic Protein 2 Suppresses the Stemness Maintenance of Cancer Stem Cells in Hepatocellular Carcinoma via the MAPK/ERK PathwayCancer Management and Research 2021; : 773 doi: 10.2147/CMAR.S281969
7
Yuhong Jiang, Xin Zhuo, Xiujuan Fu, Yue Wu, Canquan Mao. Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR TransactivationFrontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.625289
8
Hendrik Ungefroren, Frank Gieseler, Roland Kaufmann, Utz Settmacher, Hendrik Lehnert, Bernhard Rauch. Signaling Crosstalk of TGF-β/ALK5 and PAR2/PAR1: A Complex Regulatory Network Controlling Fibrosis and CancerInternational Journal of Molecular Sciences 2018; 19(6): 1568 doi: 10.3390/ijms19061568
9
Yuhong Jiang, Junxian Lim, Kai‐Chen Wu, Weijun Xu, Jacky Y. Suen, David P. Fairlie. PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFRBritish Journal of Pharmacology 2021; 178(4): 913 doi: 10.1111/bph.15332